About New Amsterdam Pharma
New Amsterdam Pharma (Nasdaq: NAMS) is a clinical-stage biopharmaceutical company aiming to improve patient care in populations with metabolic diseases. The company is investigating obicetrapib, an oral, low-dose, and once-daily CETP inhibitor as the preferred, LDL-C-lowering therapy for high-risk cardiovascular disease patients. The company was founded in 2019 and is based in Naarden, Netherlands.
Latest New Amsterdam Pharma News
Jun 1, 2023
Healio Coverage Disclosures: Maki reports receiving research grants from 89bio, Beren Therapeutics, Cargill, General Mills, Greenyn, Hass Avocado Board, Indiana University Foundation, Matinas BioPharma, National Cattleman’s Beef Association/Beef Checkoff, National Dairy Council, Naturmega, NeuroEnergy Ventures, Pepsico and Pharmavite; consulting for 89bio, Beren Therapeutics, Bragg Live Products, Campbell’s, Eli Lilly and Co., General Mills, Medifast, National Cattleman’s Beef Association/Beef Checkoff, New Amsterdam Pharma, North Sea Therapeutics and Seed; and serving on advisory boards for 89bio, Matinas BioPharma and the National Dairy Council. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact email@example.com . Back to Healio The National Lipid Association (NLA) Scientific Sessions will be held June 1-4 in Atlanta. NLA President Kevin C. Maki, PhD, CLS, FNLA, FTOS, FACN, discussed what attendees can expect from the 4-day meeting. The National Lipid Association Scientific Sessions will be held today to Sunday and will spotlight statements on nutrition in adults with dyslipidemia, include sessions on the integration of lipid guidelines in clinical practice and more. Healio | Cardiology Today spoke with NLA President Kevin C. Maki, PhD, CLS, FNLA, FTOS, FACN, chief scientist at Midwest Biomedical Research and adjunct professor and dean’s eminent scholar at Indiana University School of Public Health, about the topics covered at this year’s scientific session in Atlanta and how they could inform clinical practice. The National Lipid Association Scientific Sessions will take from Thursday, June 1 through Sunday, June 4, in Atlanta. Image: Adobe Stock “We have an opening session where there is going to be discussion of ongoing and recently completed clinical trials: emerging nonstatin therapies treating various lipid disorders, as an example,” Maki told Healio. Taking place today at 4 p.m. EST, the opening session, “The Latest in Lipid Lowering Therapy – It’s Not Just a Phase,” will be moderated by Christie M. Ballantyne, MD, FNLA, and feature presentations including: Contemporary Clinical Trials in Familial Hypercholesterolemia – presented by Michael Shapiro, DO, MCR, FNLA; Triglycerides Trials – presented by Zahid Ahmad, MD, FNLA; and Lipid Disorder in The Age of Geonomics: Emerging Nonstatin LDL-Lowering Agents – presented by Maya S. Safarova, MD, FNLA. “Moving on to the next day, there is going to be a great session about atherosclerotic plaque biology and the interplay between inflammation, plaque stability and thrombotic complications,” Maki told Healio. “An event occurs when you have a plaque. There is damage to the plaque and a thrombus forms and causes acute events. We’re learning a lot more about that and that session is going to have presentations from Peter Libby, MD, and Paul M. Ridker, MD, MPH, from Harvard.” The aforementioned session will be held Friday at 9 a.m. EST, followed by the NLA incoming president’s address, given by Daniel E. Soffer, MD, FNLA, at 10:10 a.m. EST and the W. Virgil Brown Distinguished Achievement Award and Lectureship at 10:30 a.m. EST. Session II, “Integrating Prevention Guidelines in Clinical Practice – Teaching Pearls from the Experts,” will take place Friday at 12:15 p.m. EST, and feature presentations including: Young Primary Prevention Patient – To Treat or Not to Treat? – presented by Aneesha Thobani, MD; High-Risk Polyvascular Patient – How do I Prioritize Next Secondary Prevention Steps? – presented by Shireen Khoury, MD, MPH; and Cardiometabolic Disease Patient – How Do I Approach Residual Risk? – presented by Chad Morreale, DO. “[Session II] is also going to be a great session and very practical. The trouble is that guidelines are always coming out, and it’s hard for clinicians to keep up with the new recommendations and how the old set of guidelines differ from the new set,” Maki said. “So it’s really helpful to have these sessions where the guidelines are summarized and have discussions about how these guidelines can be implemented in clinical practice including the challenges and barriers to implementation.” Saturday will feature presentations of two NLA scientific statements. “One statement came out recently on LDL cholesterol measurement and control as a quality metric. So we are hoping that CMS will readopt measurement and control of LDL cholesterol as a quality metric. We put out a joint paper with the American Society for Preventive Cardiology emphasizing the importance of LDL cholesterol measurement and control as a quality metric in health care systems,” Maki said. “The other paper that’s coming out is a clinical perspective on nutrition interventions for adults with dyslipidemia. Last year, there was a clinical perspective put out on nutrition interventions for children and adolescents with dyslipidemia. This one is specifically for adults and how clinicians can work, especially with dietitians, to help their patients adopt healthier diets and address some of the specific concerns about elevated LDL cholesterol, elevated triglycerides and those with a combination of both.” Also on Saturday will be Session VI, “Registries of Lipid Management and their Impact on Guidelines and Policy – An Update,” and will include clinical updates from the following registries: The GOULD Registry – presented by Robert S. Rosenson, MD, FNLA; The CASCADE FH Registry – presented by Mary Card, MBA, RD; The EAS FH Studies Collaboration – The Global Registry of FH – presented by Antonio J. Vallejo-Vaz, MD, PhD; and The SANTORINI/HEYMANS Registries – presented by Kausik K. Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab). “This is a session that occurred at the European Atherosclerosis Society meeting about a week ago and will be repeated here in Atlanta. It is going to be co-moderated by [Ray] and myself and will be about various registries used to track patients with different conditions like familial hypercholesterolemia, and also to evaluate how people are being treated,” Maki told Healio. “It’s going to be a great meeting and I’m looking forward to passing the baton over to [Soffer] as the incoming president,” Maki said. “For me, it’s the culmination of my year as president.” Healio is a media partner of the NLA Scientific Sessions. The Healio team will provide coverage from the meeting, including reports on the sessions above and more. Follow along at this link and on Twitter at @CardiologyToday. For more information on NLA, visit www.lipid.org/meetings/sessions/home . Reference:
New Amsterdam Pharma Frequently Asked Questions (FAQ)
When was New Amsterdam Pharma founded?
New Amsterdam Pharma was founded in 2019.
Where is New Amsterdam Pharma's headquarters?
New Amsterdam Pharma's headquarters is located at Gooimeer 2-35, Naarden.
What is New Amsterdam Pharma's latest funding round?
New Amsterdam Pharma's latest funding round is Reverse Merger.
How much did New Amsterdam Pharma raise?
New Amsterdam Pharma raised a total of $196M.
Who are the investors of New Amsterdam Pharma?
Investors of New Amsterdam Pharma include Frazier Lifesciences, Peter Thiel, Medpace, Ascendant Capital, JVC Investment Partners and 11 more.